Cytomorphology of Non-Small Cell Lung Carcinoma with MET Exon 14 Skipping Mutations

被引：0
|
作者：
Labiano, Tania [1 ]
Echegoyen, Ana [2 ]
Moneo, Marta [2 ]
Elizalde, Jesus [2 ]
Guerrero, David [2 ]
机构：
[1] Hosp Univ Navarra, Cizur Menor, Spain
[2] Complejo Hosp Navarra, Pamplona, Spain
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
349
引用
收藏
页码：S438 / S439
页数：2
相关论文
共 50 条
  • [41] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [42] Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
    Ahn, Linda
    Alexander, Terri
    Vlassak, Soetkin
    Berghoff, Karin
    Lemmens, Liesbeth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (05) : 543 - 551
  • [43] Immunotherapy for stage IV non-small cell lung cancer patients with MET exon 14 skipping mutation
    Kuon, J.
    Blasi, M.
    Shah, R.
    Christopoulos, P.
    Stenzinger, A.
    Kazdal, D.
    Herth, F. J.
    Heussel, C. P.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 172 - 172
  • [44] Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
    Minne, Rachel L.
    Luo, Natalie Y.
    Traynor, Anne M.
    Huang, Minxuan
    Detullio, Luisina
    Godden, Jen
    Stoppler, Melissa
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [45] Molecular cytopathology diagnosis of a lung neoplasm: Case report of an unusual non-small cell carcinoma with MET exon 14 skipping mutation
    Hosseini, S. Mohsen
    Khanafshar, Elham
    Seeley, Eric J.
    Ruiz-Cordero, Roberto
    DIAGNOSTIC CYTOPATHOLOGY, 2021, 49 (07) : E258 - E261
  • [46] MET Exon 14 Skipping Mutations Essential Considerations for Current Management of Non-Small-Cell Lung Cancer
    Davies, Kurtis D.
    Ritterhouse, Lauren L.
    Snow, Anthony N.
    Sidiropoulos, Nikoletta
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (08): : 841 - 843
  • [47] Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Suzawa, Ken
    Offin, Michael D.
    Kurzatkowski, Christopher
    Liu, Daniel
    Vojnic, Morana
    Smith, Roger S.
    Mattar, Marissa
    Khodos, Inna
    de Stanchina, Elisa
    Sabari, Joshua K.
    Lockwood, William W.
    Drilon, Alexander E.
    Ladanyi, Marc
    Somwar, Romel
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations e final report
    Kato, Terufumi
    Ogura, Tatsuya
    Sato, Masashi
    Kojima, Risa
    Song, Bingbing
    Horii, Eisuke
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2023, 34 : S1420 - S1421
  • [49] Prevalence of MET exon 14-mutations or MET amplification in non-small cell lung cancer in Swiss patients
    Prince, S. Savic
    Bihl, M.
    Eppenberger-Castori, S.
    Matter, M. S.
    Zellweger, N.
    Rothschild, S. I.
    Bubendorf, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S700 - S700
  • [50] Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
    Cortot, Alexis
    Le, Xiuning
    Smit, Egbert
    Viteri, Santiago
    Kato, Terufumi
    Sakai, Hiroshi
    Park, Keunchil
    Camidge, D. Ross
    Berghoff, Karin
    Vlassak, Soetkin
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (03) : 195 - 207
12345